Core Viewpoint - CloudTop New Horizon announced that it will present seven new real-world data studies at the 18th International Symposium on IgA Nephropathy from September 17 to 20, highlighting the clinical value of its treatment in IgA nephropathy [1] Group 1: Clinical Efficacy - The research results demonstrate significant clinical value in "etiological treatment, early intervention, and long-term treatment" [1] - Real-world medication confirms the value of etiological treatment [1] - Early intervention is proven to be important for reducing proteinuria and stabilizing kidney function [1] Group 2: Long-term Data - Over nine months of extended treatment data provides strong evidence for long-term efficacy and safety [1] - The evidence addresses the limitations of randomized controlled trials (RCTs) in clinical application scenarios [1] - The findings enrich treatment strategies for IgA nephropathy [1]
云顶新耀耐赋康7项真实世界数据将亮相第18届IgA肾病国际研讨会